In recent years, the number of protein'based pharmaceuticals reaching the marketplace has increased exponentially. The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution. It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration. These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories. The growth of protein drug products is having a significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.Highlights' Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing and probable future protein drugs' Examines protein delivery design issues, packaging, distribution and technology factors' Assesses the role of protein formulation decisions on therapeutic protein commercialization and market potential' Examines historical protein drug data for nine major therapeutic segments and provides forecasts by disease segment to 2016' Profiles therapeutic protein companies, their commercial products, product development activity, and business strategies

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets
and Forecasts
Published on April 2012
Report Summary
In recent years, the number of protein'based pharmaceuticals reaching the marketplace has increased exponentially. The clinical
application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution. It therefore becomes
critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic
and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for
parenteral administration. These combination drug-device products, where the drug and device are clinically tested and approved as
a single product entity, are becoming one of the fastest new drug categories. The growth of protein drug products is having a
significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is
occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability
targets and pharmacokinetic profiles of specific drug therapies.
Highlights
' Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing and probable
future protein drugs
' Examines protein delivery design issues, packaging, distribution and technology factors
' Assesses the role of protein formulation decisions on therapeutic protein commercialization and market potential
' Examines historical protein drug data for nine major therapeutic segments and provides forecasts by disease segment to 2016
' Profiles therapeutic protein companies, their commercial products, product development activity, and business strategies
Table of Content
Executive Summary
Protein Therapeutics Market Dynamics
The Protein Therapeutics Marketspace
Clinical Trials and Drug Approvals
The Competitive Landscape
Demographics, Managed Care and Growth
Risks and Opportunities
Therapeutic Protein Commercialization - Success Factors
Formulating Protein Drugs
Formulation Strategies
Stability
Half'Life & Therapeutic Protocols
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts (From Slideshare) Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Immunogenicity
Protein Formulation Technologies
Post'translational Modification
Encapsulation Technologies
Lyophilization
Dosing Frequency and Treatment Compliance
Protein Packaging & Delivery
Injection
Pen Injectors - Dominant in Chronic Disease
Prefilled Syringes - Evolving Technology, Expanding Reach
Emerging Protein Injection Options
Inhalation
Dry Powder Inhalers -' Stability at a Price
Sprays/Aerosols - The Technical Challenges
Development-stage Packaging & Delivery Technologies
Oral
Proprietary Processes and Pipeline Prospects
Commercialization Potential & Risk Factors
Transdermal
Transdermal - Obstacles and Limitations
Microneedles - Engineering & Economics
Protein Drug Distribution Strategies
Protein Drugs ' Drug Classes and Therapeutic Targets
Antibodies
Enzymes
Growth Factors
Hematopoietics
Hormones
Immune Modulators
Other Protein Therapy Classes
Protein Drug Therapeutics ' Disease Segment Analysis & Forecasts
Autoimmune Diseases
Dominance of Antibodies & Cytokines
B-Cell Depleting Agents
Interferons
Interleukin Receptor Agonists
TNF Inhibitors
T-Cell Blocking Agents
Development-stage Candidates
Demand Patterns and Forecasts
Hematology
Anemia
Hemoglobinuria
Thrombocytopenia
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts (From Slideshare) Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Demand Patterns and Forecasts
Hereditary Diseases
Infectious Diseases
Hepatitis
RSV
Demand Patterns and Forecasts
Hormone Replacement
Increasing Competition in a Crowded Market
Demand Factors and Forecasts
Oncology
Key Therapeutic Sectors & Therapeutic Target Selection
Expanding Indications & Therapeutic Endpoints
Leading Oncology Protein Drug Products
Pipeline Candidates
Demand Data and Forecasts
Reproductive Medicine
Dominance of Leutinizing Hormones
Demand Data and Forecasts
Transplantation/Organ Rejection
Approve Protein Drugs
The Market Opportunity
Emerging Therapeutic Segments
Market and Regulatory Factors
Regulatory Issues
Ease'of'Use and Patient Compliance
IP and Biosimilars
Protein Drug Therapeutics - Company Profiles
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts (From Slideshare) Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 3 850.00 Quantity: _____
Site License--USD 5 500.00 Quantity: _____
Corporate License--USD 7 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts (From Slideshare) Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts (From Slideshare) Page 5/5